Literature DB >> 15661156

Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses.

J B Johnston1, Steven H Nazarian, Renato Natale, Grant McFadden.   

Abstract

Recent studies have indicated a critical role for interferon (IFN)-mediated antiviral responses in the host range of myxoma virus (MV), a pathogenic poxvirus of rabbits. To investigate the contribution of IFN to MV tropism in nonleporine cells, primary human dermal fibroblasts (HDFs) were tested for permissiveness to MV infection. Low-passage HDFs that underwent fewer than 25 population doublings (PD) were fully permissive for MV infection, supporting productive virus replication and cell-to-cell spread. In contrast, early and late viral gene expression was detectable in high-passage HDF (>75 PD), but MV failed to generate infectious progeny and could not form foci in these cells. Vesicular stomatitis virus (VSV) plaque reduction assays confirmed that constitutive IFN production progressively increased as HDFs were passaged, concurrent with an increase in the expression of transcripts for type I IFN and IFN-responsive genes involved in antiviral responses. These findings correlated with the enhanced sensitivity of higher-passage HDF to inducers of type I IFN responses, such as dsRNA. Furthermore, pretreatment of low-passage HDF with type I IFN abrogated MV spread and replication while treatment of mature HDF with neutralizing antibodies to IFN-beta, but not IFN-alpha, restored the capacity to form foci. These findings emphasize the importance of post-entry events in determining the permissiveness of human cells to MV infection and support a critical role for innate type I IFN responses as key determinants of poxvirus host range and species restriction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661156     DOI: 10.1016/j.virol.2004.11.030

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism.

Authors:  Svitlana Grekova; Rainer Zawatzky; Rita Hörlein; Celina Cziepluch; Michal Mincberg; Claytus Davis; Jean Rommelaere; Laurent Daeffler
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

2.  Translation control by protein kinase R restricts minute virus of mice infection: role in parvovirus oncolysis.

Authors:  Iván Ventoso; Juan J Berlanga; José M Almendral
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Biological characterization and next-generation genome sequencing of the unclassified Cotia virus SPAn232 (Poxviridae).

Authors:  Priscila P Afonso; Patrícia M Silva; Laila C Schnellrath; Desyreé M Jesus; Jianhong Hu; Yajie Yang; Rolf Renne; Marcia Attias; Richard C Condit; Nissin Moussatché; Clarissa R Damaso
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1.

Authors:  J B Johnston; G Wang; J W Barrett; S H Nazarian; K Colwill; M Moran; G McFadden
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Authors:  Xueqing Lun; Wenqing Yang; Tommy Alain; Zhong-Qiao Shi; Huong Muzik; John W Barrett; Grant McFadden; John Bell; Mark G Hamilton; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

6.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

7.  Ethical and philosophical consideration of the dual-use dilemma in the biological sciences.

Authors:  Seumas Miller; Michael J Selgelid
Journal:  Sci Eng Ethics       Date:  2007-12-01       Impact factor: 3.525

Review 8.  Pharmacologic and chemical adjuvants in tumor virotherapy.

Authors:  Christopher Alvarez-Breckenridge; Balveen Kaur; E Antonio Chiocca
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

9.  Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Authors:  David H Kirn; Yaohe Wang; Fabrice Le Boeuf; John Bell; Steve H Thorne
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

10.  RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages.

Authors:  Fuan Wang; Xiujuan Gao; John W Barrett; Qing Shao; Eric Bartee; Mohamed R Mohamed; Masmudur Rahman; Steve Werden; Timothy Irvine; Jingxin Cao; Gregory A Dekaban; Grant McFadden
Journal:  PLoS Pathog       Date:  2008-07-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.